An Efficacy and Safety Study of 24 Week Treatment With Mavodelpar (REN001) in Primary Mitochondrial Myopathy Patients

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2021
This is a randomized, double-blind, placebo-controlled, parallel group, multi-centre, study designed to investigate the efficacy and safety of REN001 administered once daily over a 24-week period to patients with PMM.
Epistemonikos ID: b7e5646f0f09c06927501434b4aeae2531737ad3
First added on: May 07, 2024